Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.

31 August 2024 (09:27 - 09:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Nicolas del-Cuerpo-Salinas

UNIVERSITY HOSPITAL SAN JUAN DE ALICANTE, Sant Joan d'Alacant (Spain)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on obesity and pre-diabetes: where do we stand today on prevention and treatment?

Professor E. Prescott (Copenhagen, DK)

Presentation thumbnail

Are metabolically healthy obese individuals really a benign cardiovascular group? An analysis of 162,590 participants with measures of arterial stiffness in UK BIOBANK

Doctor R. Ananda (Melbourne, AU)

Abstract Slides Video

Presentation thumbnail

Association between normal range UACR and insulin resistance and prediabetes among US adults:

Miss S. Wu (Beijing, CN)

Abstract Slides Video

Presentation thumbnail

Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

Professor S. Kahn (Seattle, US)

Abstract Slides Video

Access the full session

Session thumbnail

Obesity and pre-diabetes: where do we stand today on prevention and treatment?

The Event

Event poster

ESC Congress 2024

31 August 2024 09:27 CET

You may be interested in

Congress Session

Obesity and pre-diabetes: where do we stand today on prevention and treatment?

Congress Session

Late-Breaking Clinical Science: cardiometabolic medicine

Congress Session

What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources